Unknown PHASE3 INTERVENTIONAL 6-arm NCT02087540

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

A Randomized, Double-blind, Multi-center, Factorial Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

Sponsor: IlDong Pharmaceutical Co Ltd

Conditions Hyperlipidemia Hypertension

Interventions Placebo(for Rosuvastatin 10mg) Placebo(for Rosuvastatin 20mg) Placebo(for Telmisartan 80mg) Rosuvastatin 10mg Rosuvastatin 20mg Telmisartan 80mg

Updated 6 times since 2017 Last updated: Mar 13, 2014 Started: May 31, 2013 Primary completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02087540, this PHASE3 trial focuses on Hyperlipidemia and Hypertension and remains ongoing. Sponsored by IlDong Pharmaceutical Co Ltd, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

IlDong Pharmaceutical Co Ltd

Data source: IlDong Pharmaceutical Co Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea